当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

Abstract：

:In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patients were chronologically divided into a derivation cohort (2010-2012, n = 2180) and a validation cohort (2013-2014, n = 1490). Haploidentical donors were excluded. The incidence of first clinically significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) at 1, 3, and 6 months in the derivation cohort was 13.8%, 38.5%, and 39.6%, respectively. CMV-seropositive donor, unrelated donor (HLA matched 10/10 or HLA mismatched 9/10), myeloablative conditioning, total body irradiation, antithymocyte globulin, and mycophenolate mofetil significantly and independently affected the incidence of 3-month infection. These six factors were selected to build up the prognostic model. Four risk groups were defined: low, intermediate-low, intermediate-high, and high-risk categories, with a 3-month predicted incidence of first clinically significant CMV infection in the derivation cohort of 22.2%, 31.1%, 45.4%, and 56.9%, respectively. This score represents a framework for the evaluation of patients who are at risk of developing clinically significant CMV infection following allo-HCT. Prospective studies using this score may be of benefit in assessing the value of anti-CMV prophylaxis in well-defined patient cohorts.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

doi

10.1038/s41409-020-01178-6

subject

Has Abstract

pub_date

2020-12-18 00:00:00

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-020-01178-6

pub_type

杂志文章

在线工具

Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.